Patents by Inventor SUZETTE BELDER-CARR

SUZETTE BELDER-CARR has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule
    Patent number: 10052360
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: August 21, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20160158318
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: February 19, 2016
    Publication date: June 9, 2016
    Inventors: Robert COHEN, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Methods for treating scleroderma by administering a soluble CTLA4 molecule
    Patent number: 9296808
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: March 29, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHODS FOR TREATING SCLERODERMA BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20140286948
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as scleroderma, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: February 28, 2014
    Publication date: September 25, 2014
    Inventors: Robert COHEN, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule
    Patent number: 8722632
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: May 13, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule
    Patent number: 8703718
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 22, 2014
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert Cohen, Suzette Belder-Carr, David Hagerty, Robert James Peach, Jean-Claude Becker
  • METHODS FOR TREATING JUVENILE RHUMATOID ARTHRITIS BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20130251713
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as juvenile rheumatoid arthritis, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 26, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: ROBERT COHEN, SUZETTE BELDER-CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER
  • METHODS FOR TREATING SJOGRENS SYNDROME BY ADMINISTERING A SOLUBLE CTLA4 MOLECULE
    Publication number: 20130230518
    Abstract: The present invention relates to compositions and methods for treating autoimmune diseases, such as Sjogren's syndrome, by administering to a subject a CTLA4 molecule that block endogenous B7 molecules from binding their ligands.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 5, 2013
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: ROBERT COHEN, SUZETTE BELDER-CARR, DAVID HAGERTY, ROBERT JAMES PEACH, JEAN-CLAUDE BECKER